ArticleMedical archives (Sarajevo, Bosnia and Herzegovina)2025
Genetic Abnormalities After Chorionic Villus Sampling of Pregnant Women at Fetal Intervention Center of Hanoi Obstetrics and Gynecology Hospital.
Article in Medical archives (Sarajevo, Bosnia and Herzegovina), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chorionic villus sampling (CVS) refers to a procedure in which samples of the placenta are obtained for prenatal genetic diagnosis, generally in the first trimester after 10 weeks of gestation. Objective: The purpose of this study was to evaluate the effectiveness of chorionic villus sampling technique in prenatal diagnosis at Phu San Ha Noi hospital. Methods: 96 pregnants who underwent chorionic villus sampling from January 2022 to December 2024 were studied. The indications for CVS include: Abnormal results of aneuploidy screening, structural anomaly on first-trimester ultrasound examination, parent is a carrier of a balanced translocation, other structural chromosome disorder, monogenic disorder or previous pregnancy with a chromosome abnormality or genetic disorder. The samples were obtained transabdominally, cultured and analysed using cytogenetic and/or molecular techniques when needed. QF-PCR test was applied first in the cultured samples to exclude maternal cell contamination. Results: Among 96 women underwent CVS, there were 34 cases have high-risk results of aneuploidy screening. All 33 women with high-risk NIPT test had the CVS results consistent with the screening test. 46 cases had parents carring a balanced translocation, structural chromosome disorder or monogenic disorders. The remaining 16 women didn't have any aneuploidy screening test and had morphological abnormalities on ultrasound. The overall abnormality detection rate was 75%. There were no cases of miscarriage, amniotic fluid leakage, premature rupture of membranes or infection. Conclusions: CVS is an effective technique in prenatal diagnosis. It can be carried from 10 weeks of gestation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.